• 1
    Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330: 25762.
  • 2
    Freeman J, Wilcox MH. Antibiotics and Clostridium difficile. Microb Infect 1999; 1: 37784.
  • 3
    Naber KG, Adam D, Expertengruppe der Paul-Ehrlich-Gesellschaft fuer Chemotherapie e. V. Einteilung der fluorchinolone. Chemother J 1998; 2: 668.
  • 4
    Van de Leur JJ, Vollard EJ, Janssen AJ et al. Influence of low dose ciprofloxacin on microbial colonization of the digestive tract in healthy volunteers during normal and during impaired colonization resistance. Scand J Infect Dis 1997; 29: 297300.
  • 5
    Rafferty ME, Baltch AL, Smith RP et al. Comparison of restriction enzyme analysis, arbitrarily primed PCR, and protein profile analysis typing for epidemiologic investigation of an ongoing Clostridium difficile outbreak. J Clin Microbiol 1998; 36: 295763.
  • 6
    Cohen SH, Tang YJ, Rashmani D et al. Persistence of an endemic (toxigenic) isolate of Clostridium difficile in the environment of a general medicine ward. Clin Infect Dis 2000; 30: 9524.
  • 7
    Blondeau JM. Expanded activity and utility of the new fluoroquinolones: a review. Clin Ther 1999; 21: 340.
  • 8
    Ackermann G, Tang YJ, Rodloff AC et al. In-vitro activity of sitafloxacin against Clostridium difficile. J Antimicrob Chemother 2001; 47: 7223.
  • 9
    Ackermann G, Tang YT, Kueper R et al. Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in the gyrA gene. Antimicrob Agents Chemother 2001; 45: 234853.
  • 10
    Alonso R, Pelaez T, Gonzales-Abad MJ et al. In vitro activity of new quinolones against Clostridium difficile. J Antimicrob Chemother 2001; 47: 1957.
  • 11
    Wilcox MH, Fawley W, Freeman J et al. In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates. J Antimicrob Chemother 2000; 46: 5515.
  • 12
    Sanders CC. Mechanisms responsible for cross-resistance and dichotomous resistance among the quinolones. Clin Infect Dis 2001; 32: S18.
  • 13
    Gumerlock PH, Tang YJ, Weiss JB et al. Specific detection of toxigenic strains of Clostridium difficile in stool specimens. J Clin Microbiol 1993; 31: 50711.
  • 14
    Cohen SH, Tang YT, Silva J Jr. Molecular typing methods for the epidemiological identification of Clostridium difficile strains. Exp Rev Mol Diagn 2001; 1: 8998.
  • 15
    National Committee for Clinical Laboratory Standards. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard M11-A4. Wayne, PA: NCCLS, 1997.
  • 16
    Cole ST, Brosch R, Parkhill J et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393: 53744.
  • 17
    Fraser CM, Norris SJ, Weinstocks GM et al. Complete genome sequence of Treponema pallidum, the syphilis spirochete. Science 1998; 281: 37588.
  • 18
    Tomb JF, White O, Kerlavage AR et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 1997; 388: 53947.